Lv2
130 积分 2024-09-13 加入
Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial
12小时前
已完结
Adipose tissue ageing: implications for metabolic health and lifespan
1个月前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
3个月前
已完结
Semaglutide and Tirzepatide to Treat Obesity
3个月前
已完结
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
3个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
3个月前
已完结
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
4个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
6个月前
已完结
Sub‐chronic administration of AM6545 enhances cognitive performance and induces hippocampal synaptic plasticity changes in naïve mice
6个月前
已完结
Endothelial insulin resistance induced by adrenomedullin mediates obesity-associated diabetes
8个月前
已完结
皖公网安备34019202002308
